Pulmatrix, Inc. Stock

PULM

US74584P3010

Biotechnology & Medical Research

Market Closed - Nasdaq 06:30:00 22/08/26 am AEST			5-day change	1st Jan Change
1.495 ^USD	-0.33%		-2.92%	-32.96%

13/08	Pulmatrix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
15/05	Pulmatrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Analysts' recommendations: Pulmatrix, Inc.

31/03/22	HC Wainwright Adjusts Pulmatrix's Price Target to $10 from $5, Keeps Buy Rating	MT
13/04/21	Pulmatrix : HC Wainwright Adjusts Pulmatrix' Price Target to $5 From $10, Keeps Buy Rating	MT

More recommendations

Press Releases: Pulmatrix, Inc.

13/08	Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger	PR
15/05	Pulmatrix Announces First Quarter 2026 Financial Results	PR
21/04	Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger	PR
13/04	PULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its Shareholders	BU
26/03	Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan	PR

More press releases

Managers and Directors: Pulmatrix, Inc.

Manager	Title	Age	Since
Peter Ludlum CEO	Chief Executive Officer	70	20/07/2024

Director	Title	Age	Since
Richard Batycky BRD	Director/Board Member	58	01/11/2019
Christopher Cabell BRD	Director/Board Member	57	23/06/2020
Todd Bazemore BRD	Director/Board Member	55	01/10/2020

More insiders

Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Companyâ€™s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrixâ€™s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
21/08/26	USD 1.495	-0.33%	39,623
20/08/26	USD 1.500	-1.32%	22,245
19/08/26	USD 1.520	-1.94%	7,823
18/08/26	USD 1.550	-0.64%	6,920
17/08/26	USD 1.560	+1.30%	12,287

Delayed Quote Nasdaq

More quotes

Market Cap	5.46M 4.68M 4.38M 4.01M 7.52M 522M 7.62M 51.7M 20.16M 262M 20.5M 20.06M 868M	P/E 2024	-2.67x	P/E 2025	-1.58x
Enterprise Value	1.37M 1.18M 1.1M 1.01M 1.89M 131M 1.91M 12.99M 5.07M 65.95M 5.15M 5.04M 218M	EV / Sales 2024	2.05x	EV / Sales 2025	-
Free-Float	99.23%	Yield 2024 *	-	Yield 2025	-

13/08	Pulmatrix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
15/05	Pulmatrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
22/04	Pulmatrix, Inc. announced that it has received $1 million in funding	CI
21/04	Pulmatrix announces closing of preferred stock transaction as part of planned merger	RE
27/03	Eos SENOLYTIX, Inc. entered into an Agreement and Plan of Merger and Reorganization to acquire Pulmatrix, Inc. in a reverse merger transaction.	CI
26/03	Pulmatrix, Inc. announced that it expects to receive $1 million in funding	CI
03/03	Pulmatrix announces termination of prior planned merger and continues pursuit of alternative merger opportunities	RE
28/02	Cullgen Inc. cancelled the acquisition of Pulmatrix, Inc. in a reverse merger transaction.	CI
27/02	Pulmatrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
19/12	Pulmatrix and Cullgen continue to pursue merger	RE
17/10/25	Pulmatrix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
16/10/25	Biopharma Pulmatrix's Q3 revenue drops to $0 as trial ends, plans asset divestment	RE
06/08/25	Pulmatrix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI

1 day	-0.33%
1 week	-2.92%
Current month	-14.08%
1 month	-12.06%
3 months	+9.12%
6 months	-47.43%
Current year	-32.96%

1 week	1.49	1.62
1 month	1.45	1.8
Current year	1.16	3.4
1 year	1.16	5.5
3 years	1.16	10.4
5 years	1.16	20.8
10 years	1.16	1,396

Date	Insider	Type	Main position	Quantity	% Market Cap.
26/1/23	Michael Higgins	Free	Chairman	2,436	0.0669%
26/1/23	Christopher Cabell	Free	Director	1,700	0.0467%
26/1/23	Richard Batycky	Free	Director	1,700	0.0467%

Pulmatrix, Inc. Stock

Stocks

PULM

US74584P3010

Biotechnology & Medical Research

Valuation: Pulmatrix, Inc.

Chart: Pulmatrix, Inc.

Latest news : Pulmatrix, Inc.

Analysts' recommendations: Pulmatrix, Inc.

Press Releases: Pulmatrix, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Pulmatrix, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PULMATRIX, INC.	-0.33%	-2.92%	-66.52%	-39.72%	5.46M
WUXI APPTEC CO., LTD.	-3.00%	+2.27%	+77.60%	+109.33%	72.12B
ARGENX SE	+1.90%	+23.53%	+56.60%	+97.76%	65.85B
BIONTECH SE	+5.12%	+25.22%	+5.24%	-0.82%	29.28B
INSMED INCORPORATED	+0.55%	+1.64%	-5.15%	+471.68%	27.47B
WUXI BIOLOGICS (CAYMAN) INC.	+2.74%	+12.98%	+62.84%	+28.14%	26.7B
GENMAB A/S	+0.47%	+6.12%	+36.66%	-13.79%	20.06B
PHARMAESSENTIA CORPORATION	+1.82%	-6.67%	+247.46%	+393.10%	18.22B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.94%	+3.36%	+18.55%	+532.94%	16.4B
EXELIXIS, INC.	+0.73%	+5.54%	+39.71%	+153.07%	13.4B
Average	+1.09%	+7.24%	+47.30%	+173.17%	28.95B
Weighted average by Cap.	+0.74%	+9.48%	+59.04%	+157.80%

	2024	2025
Net sales	7.81M 6.69M 6.26M 5.73M 10.75M 747M 10.89M 73.92M 28.83M 375M 29.31M 28.67M 1.24B	-
Net income	-9.56M -8.19M -7.66M -7.01M -13.16M -915M -13.34M -90.52M -35.3M -459M -35.89M -35.11M -1.52B	-5.16M -4.42M -4.14M -3.79M -7.11M -494M -7.2M -48.88M -19.06M -248M -19.38M -18.96M -821M
Net Debt	-9.52M -8.16M -7.63M -6.99M -13.11M -911M -13.28M -90.16M -35.16M -458M -35.75M -34.97M -1.51B	-4.09M -3.5M -3.28M -3M -5.63M -391M -5.7M -38.71M -15.1M -196M -15.35M -15.02M -650M